Gary Mansfield

Gary Mansfield, PhD, serves as Principal at Gene-X BioConsulting, LLC, specializing in preclinical strategies for AAV gene therapies targeting rare diseases since May 2019. Additional roles include Senior Consultant for product development at Endsulin and previous positions as Chief Development Officer at Aspa Therapeutics and BridgeBio, where responsibilities encompassed budget management, scientific team oversight, and collaboration with CROs and partners. With experience at American Gene Technologies as VP of Preclinical Development and Director of Preclinical Operations at Mesoblast, Gary has a proven track record in managing preclinical programs and developing operational strategies. A background in biologics development at WuXi AppTec and leadership roles at VIRxSYS Corporation and Intronn Inc. contribute to Gary's extensive experience in advancing gene therapy projects from discovery to clinical phases. Educational qualifications include a Bachelor of Science in Plant Biology and Marine Biology from UCNW Bangor and a PhD in Cell/Cellular Biology and Anatomical Sciences from the University of Nottingham.